Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404617 | 0.92 | LMNA (0.43) | LMNAHPGD | |
| SCHEMBL10285908 | 0.92 | LMNA (0.46) | LMNAHPGDEPHX2NR1H4HDAC3 | |
| SCHEMBL404010 | 0.91 | LMNA (0.45) | LMNAHPGD | |
| SCHEMBL4877991 | 0.91 | HDAC8 (0.41) | HDAC3HDAC8HDAC6 | |
| SCHEMBL404175 | 0.90 | LMNA (0.44) | LMNAHPGD | |
| SCHEMBL463230 | 0.90 | LMNA (0.44) | LMNAHPGD | |
| SCHEMBL1105508 | 0.90 | RECQL (0.45) | — | |
| SCHEMBL13244514 | 0.90 | RECQL (0.45) | — | |
| SCHEMBL404255 | 0.90 | RECQL (0.45) | — | |
| SCHEMBL402660 | 0.89 | LMNA (0.43) | LMNAHPGDACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618087-B1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | LMNA 3397/4885HPGD 408/4885EPHX2 2566/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | LMNA 3397/4885HPGD 408/4885EPHX2 2566/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | LMNA 3397/4885HPGD 408/4885EPHX2 2566/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | LMNA 3397/4885HPGD 408/4885EPHX2 2566/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | LMNA 3397/4885HPGD 408/4885EPHX2 2566/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | LMNA 3397/4885HPGD 408/4885EPHX2 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.